Nan Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 14 Year, 7 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.00 M
- Revenue Growth 2.72%
- Profit Growth 184.40%
- Ebitda 236.49%
- Net Worth 3.55%
- Total Assets 9.43%
About Nan Pharma
Nan Pharma Private Limited (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 July 2010 and has a history of 14 years and seven months. Its registered office is in Visakhapatnam, Andhra Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Appala Nukala, Surya Girija, and Sundari Anupindi serve as directors at the Company.
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24232AP2010PTC069300
- Company No.
069300
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jul 2010
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Who are the key members and board of directors at Nan Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Appala Nukala  | Director | 05-Jul-2010 | Current |
| Surya Girija | Director | 16-Jun-2014 | Current |
| Sundari Anupindi | Director | 05-Jul-2010 | Current |
Financial Performance of Nan Pharma.
Nan Pharma Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 2.72% increase. The company also saw a substantial improvement in profitability, with a 184.4% increase in profit. The company's net worth moved up by a moderate rise of 3.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nan Pharma?
In 2019, Nan Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Apoorva Health Services Private LimitedAppala Nukala is a mutual person
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- The Karnataka Bank Limited : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 21 Sep 2012 | The Karnataka Bank Limited | ₹1.00 M | Open |
How Many Employees Work at Nan Pharma?
Unlock and access historical data on people associated with Nan Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nan Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nan Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
